Second wave of biosimilar cases sharpens patent counsel focus

Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Second wave of biosimilar cases sharpens patent counsel focus

BiosimilarCOVER.jpg

US biosimilar cases will likely settle and patent thickets could be a bugbear for companies, say three in-house counsel and three private practice lawyers

Unlock this content.

The content you are trying to view is exclusive to our subscribers.

To unlock this content:

Take a Free Trial or Login
more from across site and ros bottom lb

More from across our site

Sources at four firms explain how changes to USPTO fees provide opportunities to give clients strategic counselling
Gift this article